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Peripheral  inflammation  or  nerve  injury  induces  a  pri-
mary afferent barrage into the spinal cord, which can 
cause N-methyl d-aspartate (NMDA) receptor-  dependent 
alterations in the responses of dorsal horn sensory neu-
rons to subsequent afferent inputs. This plasticity, such as 
“wind-up” and central sensitization, contributes to the 
hyperexcitability of dorsal horn neurons and increased 
pain-related behavior in animal models, as well as clini-
cal signs of chronic pain in humans, hyperalgesia and 
allodynia. Binding of NMDA receptor subunits by the 
scaffolding  protein  postsynaptic  density  protein-95 
(PSD-95) can facilitate downstream intracellular signal-
ing  and  modulate  receptor  stability,  contributing  to 
synaptic plasticity. Here, we show that spinal delivery of 
the mimetic peptide Tat-NR2B9c disrupts the interac-
tion between PSD-95 and NR2B subunits in the dorsal 
horn and selectively reduces NMDA receptor-dependent 
events  including  wind-up  of  spinal  sensory  neurons, 
and both persistent formalin-induced neuronal activity 
and pain-related behaviors, attributed to central sensi-
tization.  Furthermore,  a  single  intrathecal  injection  of 
  Tat-NR2B9c in rats with established nerve injury-induced 
pain attenuates behavioral signs of mechanical and cold 
hypersensitivity,  with  no  effect  on  locomotor  perfor-
mance. Thus, uncoupling of PSD-95 from spinal NR2B-
containing NMDA receptors may prevent the neuronal 
plasticity involved in chronic pain and may be a success-
ful  analgesic  therapy,  reducing  side  effects  associated 
with receptor blockade.
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IntroductIon
Elevated responsiveness of spinal dorsal horn neurons to sen-
sory inputs, a phenomenon termed central sensitization, is one 
mechanism  proposed  to  contribute  to  chronic  pain  states.1,2 
Such plasticity occurs following prolonged noxious peripheral 
stimulation and involves activation of dorsal horn glutamatergic 
N-methyl d-aspartate (NMDA) receptors, triggering intracellu-
lar signaling cascades within dorsal horn sensory neurons and 
inducing events such as “wind-up.” Many human descriptions 
of this are reported.3,4 Antagonists of NMDA receptors, such as 
ketamine, dextromethorphan and MK-801, block wind-up and 
display good analgesic performance in animal models of chronic 
pain,5–7  but  their  clinical  use  is  limited  by  numerous  intoler-
able side effects due to the essential functional contribution of 
NMDA  receptors  throughout  the  central  nervous  system.8–10 
Subtype-specific  drugs,  such  as  those  which  selectively  target 
NR2B   subunit-containing receptors, have a significantly better 
side effect profile, while showing great promise as analgesics for 
neuropathic pain states.11,12 Exploring novel ways of modulating 
NMDA receptor activity without receptor blockade may be an 
even better analgesic strategy.
Postsynaptic density protein-95 (PSD-95) is a synaptic scaf-
folding protein containing three PDZ (postsynaptic density 95, 
discs large, and zonula occludens-1) domains, which allow for 
protein complex formation. The second PDZ domain can bind 
NR2 subunits of the NMDA receptor, which contain a PDZ-
binding motif (tSXV) at the C-terminus.13 PSD-95 connects the 
receptor to intracellular effector proteins, such as neuronal nitric 
oxide synthase (nNOS),14 which has been shown to be involved 
in NMDA-dependent pain.15 Knockdown of PSD-95 in the spinal 
cord using antisense has demonstrated a role for this protein in 
both the development and maintenance of nerve injury-induced 
pain,16,17 while a cyclic peptide, which blocks binding interactions 
at each of the three PDZ domains of PSD-95, also reduces behavi-
oral hypersensitivity following nerve injury.18
Although it is clear that NR2B-subtype NMDA receptors 
and PSD-95 are both individually involved in abnormal pain 
states, it remains to be seen whether a specific physical inter-
action between these two synaptic proteins is required for dor-
sal horn neuronal plasticity and the establishment of a chronic 
pain state, particularly following nerve injury. Here, for the first 
time, we have investigated the electrophysiological and behavi-
oral effects of perturbing the specific interaction between spinal 
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NR2B-containing NMDA receptors and PSD-95, using a pep-
tide-mimetic strategy, in dorsal horn wind-up and formalin-
induced central sensitization, two models of spinal nociceptive 
plasticity. In addition, we tested this exciting novel analgesic 
strategy within integrated systems in a rat model of chronic neu-
ropathic pain.
results
tat-nr2B9c perturbs the interaction  
between nr2B subunits and Psd-95
Protein expression of PSD-95 was confirmed by western immu-
noblotting in hippocampus and spinal cord dorsal horn tissue. As 
expected, PSD-95 protein was not present in dorsal root ganglion 
(Figure 1a). Thus, in the spinal cord, PSD-95 is exclusively found 
in intrinsic dorsal horn sensory neurons and not in terminating 
primary afferent fibers.
We  used  immunoprecipitation  to  reveal  physical  coupling 
between  spinal  dorsal  horn  NR2B  subunits  and  associated 
  proteins using a specific antibody against this subunit (Figure 1b). 
As expected, PSD-95 protein was coimmunoprecipitated by the 
anti-NR2B antibody, as was nNOS. Normal spinal lysate was run 
alongside immunoprecipitation samples to act as positive con-
trols, whereas CREB and P2X3 were probed as two negative con-
trol proteins, to ensure that the immunoprecipitation step had 
worked correctly. CREB is a nuclear protein and the P2X3 receptor 
is located exclusively on the central terminals of primary affer-
ents, thus these two proteins should not be found in a postsynap-
tic, membrane-associated NR2B/PSD-95 complex. Accordingly, 
both CREB and P2X3 were only detected in normal spinal tissue 
lysates and not in immunoprecipitated samples, confirming that 
nonspecific  detection  of  proteins  in  the  immunoprecipitation 
sample had not occurred. Thus, PSD-95 and nNOS are physi-
cally coupled to NR2B-containing NMDA receptors in the dorsal 
horn.
In a separate experiment, rats were pretreated via intrathe-
cal injection with either Tat-NR2BAA (125 ng) or Tat-NR2B9c 
(125 ng), 20 minutes before collection of lumbar dorsal horn   tissue. 
PSD-95 protein was coimmunoprecipitated with NR2B subunits 
by the anti-NR2B antibody, as expected, from the dorsal horn of 
rats pretreated with the control peptide   Tat-NR2BAA (Figure 1c), 
similar to that from naive rats. In contrast, coimmuno  precipitation 
of PSD-95 with NR2B subunits was markedly decreased in rats 
pretreated with the disrupting peptide Tat-NR2B9c (Figure 1c).
Thus,  spinal  delivery  of  Tat-NR2B9c  perturbs  interactions 
between PSD-95 and NR2B-containing NMDA receptors in the 
dorsal horn within 20 minutes. Since PSD-95 is only expressed 
within intrinsic dorsal horn neurons, the presence of PSD-95 pro-
tein in the immunoprecipitated sample indicates that the NR2B-
associated protein complex is present within the same intrinsic 
dorsal horn neurons, suggesting that Tat-NR2B9c has an exclu-
sively postsynaptic action in the dorsal horn.
spinal administration of tat-nr2B9c does  
not alter afferent-evoked responses but inhibits 
postdischarge of deep dorsal horn Wdr neurons
Electrically evoked responses of deep dorsal horn wide dynamic 
range (WDR) neurons due to primary afferent activity were unal-
tered following spinal Tat-NR2B9c (12.5 ng, n = 6). No changes 
were  seen  in  Aβ-fiber,  Aδ-fiber  or  C-fiber  evoked  responses 
(Figure 2a). The control peptide Tat-NR2BAA (1.25 µg, n = 6) 
also had no effect on these evoked responses, at a dose 100× 
greater than that of the active peptide. WDR neurons continue 
to  fire  action  potentials  (APs)  once  the  afferent  barrage  has 
ceased, a measure known as postdischarge, indicating the hyper-
excitability of the cell. Tat-NR2B9c produced a significant and 
robust reduction of postdischarge (Figure 2a; percentage of pre-
drug baseline = 45 ± 4 %, P < 0.01), whereas Tat-NR2BAA had 
no effect. Inhibitory effects of Tat-NR2B9c were evident by 20 
minutes   following spinal administration, peaked at ~40   minutes 
and  persisted  for  the  duration  of  the  experiment.  Predrug 
control  responses  did  not  differ  between  treatment  groups 
(Supplementary Table S1).
Wind-up of deep dorsal horn Wdr neurons  
is reduced by spinal tat-nr2B9c
The  presynaptic  “input”  (nonpotentiated  response)  as  well  as 
the “wind-up” of WDR neurons were both assessed (Figure 2b). 
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Figure 1  Postsynaptic density protein-95 (Psd-95) forms a complex 
with nr2B-subtype receptors in dorsal horn neurons and binding to 
nr2B subunits is perturbed by tat-nr2B9c. (a) Western immunoblot 
showing expression of PSD-95 in hippocampus (two left lanes), dorsal 
root ganglion (DRG) (two centre lanes), and spinal dorsal horn (two right 
lanes). βIII-tubulin served as a loading control. (b) Western immunoblots 
of normal lumbar spinal dorsal horn lysates (left two lanes) and coimmu-
noprecipitates from lumbar spinal dorsal horn lysate obtained using an 
antibody against NR2B (right two lanes), probed with antibodies against 
NR2B, neuronal nitric oxide synthase (nNOS), PSD-95, CREB, and P2X3. 
(c) Western immunoblots showing immunoprecipitates (IP, right lanes) 
from the lumbar dorsal horn of rats pretreated intrathecally with Tat-
NR2BAA  (125 ng)  or  Tat-NR2B9c  (125 ng),  20  minutes  before  being 
sacrificed, obtained using an antibody against NR2B subunits (represen-
tative of four independent experiments). Note the marked reduction in 
PSD-95 coimmunoprecipitated with NR2B subunits from the dorsal horn 
of rats pretreated with Tat-NR2B9c. Left lane shows normal dorsal horn 
lysates with no immunoprecipitation, acting as positive controls.1782  www.moleculartherapy.org  vol. 19 no. 10 oct. 2011                   
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Wind-up is the NMDA-dependent increasing response of WDR 
neurons  to  repetitive  noxious  peripheral  stimulation  at  con-
stant intensity and frequency (Figure 2c,d). Both Tat-NR2B9c 
and Tat-NR2AA had no effect on input (Figure 2b). In contrast, 
Tat-NR2B9c significantly decreased wind-up of WDR neurons 
(Figure 2b; percentage of predrug baseline = 52 ± 4 %, P < 0.05), 
whereas Tat-NR2BAA had no effect.
Therefore, Tat-NR2B9c, believed to exert its effects by disrup-
tion of binding between PSD-95 and NR2B subunits, selectively 
reduces NMDA receptor-mediated postdischarge and wind-up 
of deep dorsal horn WDR neurons, while having no effect on 
  afferent-evoked responses and input, indicating a postsynaptic 
mechanism of action.
Formalin-induced central sensitization of deep  
dorsal horn Wdr neurons is reduced by spinal 
pretreatment with tat-nr2B9c
Formalin was injected into the hindpaw receptive field and the fir-
ing response of single WDR neurons was recorded (Figure 3c). 
This stimulus produces an afferent drive with a delayed central 
NMDA component to the response. In control recordings, where 
no  drug  was  applied,  formalin  induced  a  characteristic  bipha-
sic  neuronal  firing  response  (Figure  3a;  1st  phase:  0–10  min-
utes, total APs = 9,632 ± 1,678; 2nd phase: 10–70 minutes, total 
APs = 64,071 ± 16,220; n = 11). Control pretreatment with spi-
nal Tat-NR2BAA (1.25 µg, n = 11), 20 minutes before formalin 
injection, did not alter this response (Figure 3a–c; 1st phase total 
APs = 13,970 ± 2,228, P > 0.05; 2nd phase total APs = 54,483 ± 13,673, 
P > 0.05). Spinal pretreatment with Tat-NR2B9c (12.5 ng, n = 10) 
did, however, significantly and selectively reduce 2nd phase neu-
ronal firing (Figure 3a–c; total APs = 9,695 ± 5,386, P < 0.001), 
attributed to central sensitization of spinal dorsal horn neurons.19,20 
Only a small nonsignificant reduction of neuronal firing during 
the 1st phase was observed following Tat-NR2B9c pretreatment, 
likely reflecting the inhibitory effects seen previously on postdis-
charge and wind-up. All cells recorded were characterized before 
injection of drug and formalin to ensure that cells were comparable 
between treatment groups (Supplementary Table S2).
Thus,  spinal  application  of  Tat-NR2B9c  reduces  NMDA-
mediated components of formalin-induced central sensitization 
of deep dorsal horn WDR neurons.
spinal tat-nr2B9c inhibits pain-related behaviors  
due to formalin-induced central sensitization
Having observed the inhibitory effects of Tat-NR2B9c on neuronal 
activity related to spinal plasticity, we next sought to see whether 
similar effects could be found in a behavioral assay, again using for-
malin injected into the hindpaw of freely moving and awake rats. 
As with neuronal activity, formalin induced a biphasic response 
of pain-related behaviors in rats pretreated intrathecally with the 
control peptide Tat-NR2BAA (1.25 µg, n = 11) 20 minutes before 
formalin  injection  (Figure 3d,e; 1st phase: 0–10 minutes, total 
time of pain-related behavior = 94 ± 9 seconds; 2nd phase: 10–60 
minutes, total time of pain-related behavior = 360 ± 26 seconds). 
Pretreatment  with  Tat-NR2Bc,  however,  significantly  decreased 
pain-related behavior during the 2nd phase of the response in 
a  dose-dependent  manner  (Figure  3d,e;  12.5 ng,  n  =  10,  2nd 
phase  total  time  of  pain-related  behavior  =  255  ±  13  seconds, 
P  <  0.01;  125 ng,  n  =  6,  2nd  phase  total  time  of  pain-related 
  behavior = 174 ± 16 seconds, P < 0.001). No difference was seen 
during the 1st phase between either dose of Tat-NR2B9c and the 
control peptide (Figure 3d,e; 12.5 ng, 1st phase total time of pain-
related behavior = 68 ± 8 seconds, P > 0.05; 125 ng, 1st phase total 
time of pain-related behavior = 84 ± 8 seconds, P > 0.05).
Further analysis of the different pain behaviors showed that 
rats injected with formalin spent most time licking and biting the 
injured paw, rather than lifting and flinching (Supplementary 
Figure S1). Licking and biting behavior alone also shows a strong 
biphasic  response  following  pretreatment  with  Tat–NR2BAA 
(Supplementary Figure S1a; 1st phase: 0–10 minutes, total time 
of licking and biting behavior = 83 ± 10 seconds; 2nd phase: 10–60 
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Figure  2  spinal  tat-nr2B9c  decreases  hyperexcitability  of  wide 
dynamic  range  (Wdr)  neurons. ( a)  Afferent-evoked  responses  and 
postdischarge  of  WDR  neurons  following  transcutaneous  electrical 
stimulation of the hindpaw receptive field, with spinal application of 
Tat-NR2BAA (1.25 μg) or Tat-NR2B9c (12.5 ng). (b) Effect of spinal Tat-
NR2BAA (1.25 μg) or Tat-NR2B9c (12.5 ng) on input and wind-up of 
WDR neurons. White bars represent predrug control. Data presented 
as mean ± SEM of predrug baseline responses; *P < 0.05, **P < 0.01, 
***P < 0.001 versus predrug baseline or control peptide; n = 6 in each 
group. (c,d) Examples of the wind-up of single WDR neurons follow-
ing repetitive stimulation, and in the presence of spinal (c) Tat-NR2BAA 
(1.25 μg) or (d) Tat-NR2B9c (12.5 ng).Molecular Therapy  vol. 19 no. 10 oct. 2011           1783
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minutes, total time of licking and biting   behavior = 285 ± 23 
  seconds),  which  correlates  exactly  with  the  biphasic  neuronal 
activity.  Pretreatment  with  Tat-NR2B9c  produced  a  signifi-
cant  and  dose-dependent  reduction  of  this  licking  and  biting 
behavior during the 2nd phase of the response (Supplementary 
Figure S1b; 12.5 ng, 2nd phase total time of licking and   biting 
  behavior  =  200  ±  18  seconds,  P  <  0.05;  125 ng,  2nd  phase 
total time of licking and biting behavior = 124 ± 19 seconds, 
P < 0.001). In contrast, rats spent little time lifting and flinching 
and this behavior did not follow such an obvious biphasic time 
course (Supplementary Figure S1c). There was no difference in 
total lifting and flinching behavior in either the 1st or 2nd phase 
between Tat-NR2BAA and Tat-NR2B9c groups (Supplementary 
Figure S1d).
Thus,  Tat-NR2B9c  reduces  formalin-induced  pain-related 
behaviors that are associated with spinal central sensitization via 
a selective action on the active licking and biting responses rather 
than the more reflexive lifting and flinching.
spinal tat-nr2B9c does not alter afferent-evoked 
responses but inhibits postdischarge of deep dorsal 
horn Wdr neurons in snl and sham-operated rats
Spinal nerve ligation (SNL) induces mechanical and cold hyper-
sensitivity of the injured paw,21 indicative of a neuropathic pain 
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Figure 3  spinal tat-nr2B9c reduces formalin-induced central sensitization. (a) Time course of firing of wide dynamic range (WDR) neurons fol-
lowing subcutaneous injection of formalin into the hindpaw receptive field with either no drug (control, n = 11) or following spinal pretreatment with 
Tat-NR2BAA (1.25 μg, n = 11) or Tat-NR2B9c (12.5 ng, n = 10, *P < 0.05 at 50 minutes versus Tat-NR2BAA). (b) Total neuronal activity during the 
1st phase (0–10 minutes) and 2nd phase (10–70 minutes) of the response to formalin with no drug (control) or following spinal pretreatment with 
Tat-NR2AA or Tat-NR2B9c (2nd phase, ***P < 0.001, **P < 0.01 versus no drug and Tat-NR2BAA, respectively). (c) Example rate recordings of firing 
responses of WDR neurons to formalin with no drug (control) or following spinal pretreatment with Tat-NR2BAA (1.25 μg) or Tat-NR2B9c (12.5 ng). 
(d) Time course of pain-related behaviors following subcutaneous injection of formalin into the hindpaw following intrathecal pretreatment with Tat-
NR2BAA (1.25 μg, n = 11) or Tat-NR2B9c (12.5 ng, n = 10, **P < 0.01 at 25 minutes versus Tat-NR2BAA; 125 ng, n = 6, ***P < 0.001 at 20, 25 minutes, 
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phase (10–60 minutes) of the response to formalin following spinal pretreatment with Tat-NR2AA or Tat-NR2B9c (2nd phase, 12.5 ng, **P < 0.01, 
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state. The effects of spinal administration of Tat-NR2B9c on elec-
trically evoked responses of deep dorsal horn WDR neurons were 
compared in SNL and sham-operated rats (n = 8 in each group). 
Responses of WDR neurons due to primary afferent activity were 
unaltered in both groups following spinal Tat-NR2B9c (12.5 ng). 
No  changes  were  seen  in  Aβ-fiber  Aδ-fiber  or  C-fiber  evoked 
responses  (Figure  4a).  Postdischarge,  however,  was  reduced  in 
both SNL and sham rats to a similar extent (Figure 4a; SNL: per-
centage of predrug baseline = 60 ± 11%, P < 0.01; sham: percentage 
of predrug baseline = 52 ± 13.0%, P < 0.01). This inhibitory effect 
of Tat-NR2B9c on the postdischarge of WDR neurons was similar 
to that seen in naive rats (Figure 2a). Predrug control responses 
did not differ between surgical groups (Supplementary Table S3).
Wind-up of deep dorsal horn Wdr neurons  
is reduced by spinal tat-nr2B9c in both  
snl and sham-operated rats
As in naive rats, no effect was seen with Tat-NR2B9c on input 
(nonpotentiated response) in either SNL or sham-operated rats 
(Figure 4b). In contrast, Tat-NR2B9c produced a significant inhi-
bition of wind-up in both surgery groups (Figure 4b–d; SNL: 
12.5 ng, percentage of predrug baseline = 56 ± 10%, P < 0.01, 
n = 8; sham: 12.5 ng, percentage of predrug baseline = 54 ± 12%, 
P < 0.01, n = 8). Inhibition of wind-up was comparable between 
surgical groups and to that observed in naive rats (Figure 3b).
Therefore, Tat-NR2B9c selectively reduces NMDA receptor-
mediated postdischarge and wind-up of deep dorsal horn WDR 
neurons, while having no effect on afferent-evoked responses and 
input, in both SNL and sham-operated rats. The inhibitory effect 
of Tat-NR2B9c on postdischarge and wind-up is not altered in 
neuropathy.
responses of deep dorsal horn Wdr neurons evoked 
by natural stimuli are reduced by spinal application 
of tat-nr2B9c in snl and sham-operated rats
Next, the responses of deep dorsal horn WDR neurons to natu-
ral stimuli applied to the hindpaw receptive field were assessed. 
The  predrug  brush-evoked  response  was  higher  in  sham  rats 
compared to SNL rats, though this difference was not statistically 
significant  (Supplementary  Table  S4;  sham:  mean  number  of 
APs = 473 ± 92, n = 6, SNL: mean number of APs = 367 ± 73, n = 6; 
P > 0.05). Spinal application of Tat-NR2B9c minimally reduced 
the response to brush in both surgical groups to a similar level, 
but this effect did not reach statistical significance (Figure 5a,b; 
12.5 ng, n = 6 in each group, sham: APs = 298 ± 88, P > 0.05; SNL: 
APs = 270 ± 137; P > 0.05).
Mechanical punctate stimulation of the hindpaw was delivered 
by different von Frey filaments which produced graded responses 
of WDR neurons that did not differ significantly between SNL 
and  sham-operated  rats  (Supplementary  Table  S4;  n  =  6  in 
each group; 1 g, sham: mean number of APs = 0.7 ± 0.5, SNL: 
APs = 0.3 ± 0.3; 8 g, sham: APs = 225 ± 68, SNL: APs = 227 ± 132; 
15 g, sham: APs = 606 ± 165, SNL: APs = 539 ± 140; 26 g, sham: 
APs = 821 ± 140, SNL: APs = 1,017 ± 207). Spinal application 
of Tat-NR2B9c (12.5 ng, n = 6 in each group) reduced graded 
responses  to  mechanical  stimulation  in  both  SNL  and  sham 
rats  (Figure 5c,d;  1 g,  sham:  APs  =  0.0  ±  0.0,  P  >  0.05,  SNL: 
APs = 0.2 ± 0.2, P > 0.05; 8 g, sham: APs = 32 ± 13, P > 0.05, SNL: 
APs = 28 ± 12, P > 0.05; 15 g, sham: APs = 214 ± 147, P < 0.001, SNL: 
APs = 161 ± 52, P < 0.01; 26 g, sham: APs = 413 ± 127, P < 0.001, 
SNL: APs = 693 ± 224, P < 0.01). The effects of   Tat-NR2B9c were 
similar in both surgical groups.
Graded responses of WDR neurons to thermal stimulation, 
via a water jet of different temperatures, were similar in SNL and 
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Figure  4  spinal  tat-nr2B9c  decreases  hyperexcitability  of  wide 
dynamic range (Wdr) neurons in both sham and spinal nerve liga-
tion (snl) rats. (a) Afferent-evoked responses and postdischarge of 
WDR neurons induced by transcutaneous electrical stimulation of the 
hindpaw  receptive  field  in  sham  and  SNL  rats  and  following  spinal 
application of Tat-NR2B9c (12.5 ng). (b) Effect of spinal application of 
Tat-NR2B9c (12.5 ng) on input and wind-up of WDR neurons in sham 
and SNL rats. White bars represent predrug control. Data presented as 
mean ± SEM of predrug control responses; **P < 0.01 versus predrug 
baseline; n = 8 in each group. (c,d) Examples of the wind-up of single 
WDR neurons following repetitive electrical stimulation, and in the pres-
ence of spinal Tat-NR2B9c (12.5 ng) in (c) sham and (d) spinal nerve 
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sham-operated rats (Supplementary Table S4; n = 6 in each group; 
35 °C, sham: APs = 284 ± 97, SNL: APs = 73 ± 30; 40 °C, sham: 
APs = 346 ± 98, SNL: APs = 138 ± 60; 45 °C, sham: APs = 672 ± 106, 
SNL: APs = 631 ± 205; 48 °C, sham: APs = 1,282 ± 102, SNL: 
APs  =  1,254  ±  131).  Responses  in  both  surgical  groups  were 
reduced by spinal application of Tat-NR2B9c (12.5 ng, n = 6 in each 
group) to a similar degree (Figure 5e,f; 35 °C, sham: APs = 89 ± 32, 
P > 0.05, SNL: APs = 67 ± 22, P > 0.05; 40 °C, sham: APs = 74 ± 27, 
P  >  0.05,  SNL:  APs  =  31  ±  11,  P  >  0.05;  45 °C,  sham:  APs  = 
161 ± 93, P < 0.05, SNL: APs = 99 ± 43, P < 0.001; 48 °C, sham: 
APs = 1,119 ± 340, P > 0.05, SNL: APs = 857 ± 274, P < 0.01).
Therefore,  spinal  administration  of  Tat-NR2B9c  reduces 
graded responses of deep dorsal horn WDR neurons to mechani-
cal and thermal stimulation in both SNL and sham-operated rats. 
Brush-evoked responses are minimally reduced.
nerve injury-induced behavioral mechanical and cold 
hypersensitivity is attenuated by spinal tat-nr2B9c
In a behavioral study, paw withdrawal thresholds (PWTs) and 
number  of  responses  to  acetone  of  both  hindpaws  were  mea-
sured in rats, 4 days before SNL surgery. Rats were assigned to 
Tat-NR2B9c (n = 8) or Tat-NR2BAA (n = 8) treatment groups in 
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Figure 5  spinal tat-nr2B9c reduces responses of wide dynamic range (Wdr) neurons evoked by mechanical and thermal stimulation in both 
sham and spinal nerve ligation (snl) rats. (a,b) Responses of WDR neurons to brush stimulation of the hindpaw receptive field in (a) sham and (b) 
SNL rats and following spinal application of Tat-NR2B9c (12.5 ng). (c,d) Responses of WDR neurons to mechanical stimulation of the hindpaw recep-
tive field with von Frey hairs (1, 8, 15 and 26 g) in (c) sham and (d) SNL rats and following spinal application of Tat-NR2B9c (12.5 ng). (e,f) Responses 
of WDR neurons to thermal stimulation of the hindpaw receptive field with different temperatures of water (35, 40, 45 and 48 °C) in (e) sham and 
(f) SNL rats and following spinal application of Tat-NR2B9c (12.5 ng). All data presented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001; n = 6 
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a randomized and blinded fashion. Baseline thresholds of ipsilat-
eral and contralateral paws of rats in each group were identical 
(Figure 6a; Tat-NR2BAA group: ipsilateral PWT = 10.9 ± 1.3 g, 
contralateral  PWT  =  10.6  ±  1.4 g;  Tat-NR2B9c  group:  ipsilat-
eral  PWT  =  10.6  ±  1.4 g,  contralateral  PWT  =  10.0  ±  1.2 g). 
Number  of  responses  to  acetone  (out  of  five)  was  also  com-
parable  between  hindpaws  of  rats  in  each  group  (Figure  6b; 
Tat-NR2BAA  group:  ipsilateral  acetone  responses  =  0.8  ±  0.3, 
contralateral acetone responses = 0.4 ± 0.3; Tat-NR2B9c group: 
ipsilateral acetone responses = 0.3 ± 0.2, contralateral acetone 
responses = 0.5 ± 0.3).
Assessment  of  PWTs  and  responses  to  acetone  continued 
throughout  the  postoperative  period.  On  postoperative  day  2, 
PWTs of the ipsilateral paw of rats in each treatment group had 
significantly  decreased,  indicating  mechanical  hypersensitivity, 
whereas PWTs of the contralateral paws remained at baseline lev-
els (Figure 6a; Tat-NR2BAA group: ipsilateral PWT = 1.5 ± 0.4 g, 
contralateral PWT = 9.8 ± 1.3 g, P < 0.001; Tat-NR2B9c group: 
ipsilateral PWT = 2.0 ± 0.9 g, contralateral PWT = 10.6 ± 1.5 g, 
P < 0.001). Similarly, rats developed cold hypersensitivity of the 
ipsilateral paw by day 2, as indicated by the greater number of 
responses to acetone compared to the contralateral paw (Figure 6b; 
Tat-NR2BAA group: ipsilateral acetone responses = 3.1 ± 0.5, con-
tralateral acetone responses = 0.4 ± 0.3, P < 0.001; Tat-NR2B9c 
group: ipsilateral acetone responses = 3.8 ± 0.5, contralateral ace-
tone responses = 0.8 ± 0.3, P < 0.001). These differences in PWTs 
and  responses  to  acetone  between  ipsilateral  and  contralateral 
paws were maintained throughout the postoperative period, mea-
sured up to day 14 or 16, in both treatment groups (Figure 6a,b).
Following  measurement  of  PWTs  and  acetone  responses 
on day 14 or 16, either Tat-NR2BAA (125 ng) or Tat-NR2B9c 
(125 ng)  was  delivered  spinally  to  rats  via  intrathecal  lumbar 
puncture. PWTs and responses to acetone were then remeasured 
at various time points after treatment (Figure 6a,b). In the Tat-
NR2BAA treatment group, there were no changes in PWTs or 
responses to acetone such that mechanical and cold hypersensi-
tivity persisted throughout the testing period. In contrast, treat-
ment with Tat-NR2B9c produced a reversal in both mechanical 
PWTs and responses to acetone of the ipsilateral hindpaw toward 
presurgery baseline levels and those of the contralateral paw. The 
ipsilateral PWTs of rats treated with Tat-NR2B9c were higher 
than  those  of  rats  treated  with  Tat-NR2BAA  throughout  the 
5-hour  testing  period,  with  statistically  significant  differences 
seen from 60 minutes until 2 hours after treatment (Figure 6a; 
60 minutes: Tat-NR2B9c group ipsilateral PWT = 8.1 ± 1.5 g, 
Tat-NR2BAA group ipsilateral PWT = 1.6 ± 0.2 g, P < 0.01; 90 
minutes: Tat-NR2B9c group ipsilateral PWT = 6.6 ± 1.5 g, Tat-
NR2BAA group ipsilateral PWT = 1.1 ± 0.2 g, P < 0.05; 2 hours: 
  Tat-NR2B9c group ipsilateral PWT = 8.7 ± 1.7 g, Tat-NR2BAA 
group ipsilateral PWT = 1.9 ± 0.9 g, P < 0.01). Acetone responses 
of the ipsilateral hindpaw were lower in the Tat-NR2B9c group 
than  the  Tat-NR2BAA  following  treatment  throughout  the 
5-hour  testing  period,  with  statistically  significant  differences 
at 30 minutes, 90 minutes, 3 hours, 4 hours and 5 hours after 
treatment  (Figure  6b;  30  minutes:  Tat-NR2B9c  group  ipsilat-
eral acetone response = 2.3 ± 0.3, Tat-NR2BAA group ipsilateral 
acetone response = 4.1 ± 0.2, P < 0.05; 90 minutes: Tat-NR2B9c 
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Figure  6  Intrathecal  tat-nr2B9c  attenuates  nerve  injury-induced 
mechanical  and  cold  hypersensitivity  but does  not  affect locomotor 
performance. (a) Mechanical paw withdrawal thresholds (PWTs) of spinal 
nerve ligation (SNL) rats and (b) responses to acetone at both the ipsilat-
eral (IPSI) and contralateral (CONTRA) hindpaws measured 4 days before 
SNL surgery and on postsurgical days 2, 7, 10, and 14 or 16. Rats received 
intrathecal Tat-NR2B9c (125 ng) or Tat-NR2BAA (125 ng) on day 14 or 16 
and PWTs were reassessed at 30 minutes, 60 minutes, 90 minutes, 2 hours, 
3 hours, 4 hours and 5 hours following drug administration. n = 8 in each 
group; *P < 0.05, **P < 0.01 versus ipsilateral Tat-NR2BAA group. (c) Time 
spent on the accelerating rotarod (i.e., latency to fall) before (baseline, white 
bar) and after intrathecal injection of Tat-NR2B9c (125 ng, n = 4, black bars). 
A cutoff time of 90 seconds was used. All data presented as mean ± SEM.Molecular Therapy  vol. 19 no. 10 oct. 2011           1787
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group  ipsilateral  acetone  response  =  2.6  ±  0.6,  Tat-NR2BAA 
group ipsilateral acetone response = 4.4 ± 0.4, P < 0.05; 3 hours: 
Tat-NR2B9c  group  ipsilateral  acetone  response  =  2.3  ±  0.4, 
Tat-NR2BAA  group  ipsilateral  acetone  response  =  4.5  ±  0.3, 
P  <  0.01;  4  hours:  Tat-NR2B9c  group  ipsilateral  acetone 
response  =  2.3  ±  0.5,  Tat-NR2BAA  group  ipsilateral  acetone 
response = 4.3 ± 0.4, P < 0.01; 5 hours: Tat-NR2B9c group ipsilat-
eral acetone response = 2.6 ± 0.6, Tat-NR2BAA group ipsilateral 
acetone response = 4.6 ± 0.2, P < 0.01).
Thus,  intrathecal  Tat-NR2B9c  attenuates  SNL-induced 
mechanical and cold behavioral hypersensitivity, suggesting that 
the physical interaction between NR2B-containing NMDA recep-
tors and PSD-95 is required for the maintenance of nerve injury-
induced neuropathic pain.
spinal tat-nr2B9c does not alter  
locomotor performance in the rotarod test
Performance  on  the  rotarod  was  used  to  assess  any  adverse 
effects of spinal administration of Tat-NR2B9c on locomotor 
function of rats (Figure 6c). Rats were initially trained to remain 
on the rotarod for a minimum of 60 seconds and up to 90 sec-
onds. Prior to administration of drug, rats spent an average of 
85.3 ± 2.1 seconds on the rotarod. Intrathecal lumbar puncture 
treatment with Tat-NR2B9c (125 ng, n = 4) had no effect on 
rotarod performance during the 2-hour testing period following 
treatment (mean time spent on rotarod: 20 minutes = 87.5 ± 2.5 
seconds, 40 minutes = 86.3 ± 3.8, 60 minutes = 90.0 ± 0.0, 2 
hours = 88.0 ± 2.0).
Therefore, spinal delivery of Tat-NR2B9c does not affect loco-
motor performance in rats at a dose which reverses mechanical 
and  behavioral  hypersensitivity  following  spinal  nerve  ligation 
and also pain-related behaviors due to formalin-induced central 
sensitization. The analgesic effects of Tat-NR2B9c may thus be 
attributed to alterations specifically in sensory processing.
dIscussIon
Repetitive and prolonged noxious primary afferent stimulation, 
as elicited by transcutaneous electrical stimulation, formalin-
induced inflammation and peripheral nerve damage, leads to 
NMDA receptor-mediated plastic changes in spinal neuronal 
activity, producing wind-up and central sensitization of dorsal 
horn sensory neurons, which may contribute to the manifesta-
tion of chronic pain states. We show that binding of PSD-95 to 
spinal NMDA receptors, composed specifically of NR2B sub-
units, is important for these sensitizing effects of NMDA recep-
tor activation. Perturbing such interactions with the mimetic 
peptide,   Tat-NR2B9c, reduces neuronal hyperexcitability and 
plasticity and also abnormal pain-related behaviors (Figure 7). 
In  particular,  our  findings  suggest  that  physical  coupling 
between spinal NR2B-containing NMDA receptors and PSD-95 
is crucial to the maintenance of nerve injury-induced neuro-
pathic pain.
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Figure 7  disruption of N-methyl d-aspartate (nMdA)-mediated intracellular signaling via postsynaptic density protein-95 (Psd-95) by tat-
nr2B9c. Ca2+ influx via NMDA receptors can activate intracellular effectors located in the vicinity of the channel pore. Such effectors, for example 
neuronal nitric oxide synthase (nNOS), are physically linked to the receptor via the scaffolding protein PSD-95, which directly binds to NR2B subunits 
of the NMDA receptor via its second PDZ domain. The cytoplasmic tail of NR2B subunits contains the PSD-95-binding motif ESDV. Activation of spe-
cific effectors and pathways downstream of the NMDA receptor lead to mechanisms of spinal plasticity such as wind-up and central sensitization, and 
perhaps manifestation of chronic pain states such as nerve injury-induced neuropathic pain. The intracellular introduction of the peptide Tat-NR2B9c 
uncouples NMDA receptor activation from such potentially pathological downstream signaling pathways. Tat-NR2B9c binds to PSD-95, thus prevent-
ing PSD-95 from binding to NR2B subunits. However, receptor activation and Ca2+ influx can still occur, thereby possibly minimizing side effects.1788  www.moleculartherapy.org  vol. 19 no. 10 oct. 2011                   
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Our novel electrophysiological data provide a neuronal sub-
strate for the behavioral effects of disrupting interactions between 
NMDA receptors and PSD-95. Tat-NR2B9c inhibits postdischarge 
and wind-up, two measures of dorsal horn neuronal hyperexcit-
ability  and  plasticity,  identically  in  naive,  sham  and  SNL  rats. 
Primary afferent-evoked responses and presynaptic input were 
unaltered, suggesting a postsynaptic mechanism of action. These 
highly selective electrophysiological results are similar to those 
achieved by blocking NR2B-subtype receptors.11,22 Responses of 
WDR neurons evoked by mechanical and thermal stimulation of 
the hindpaw were inhibited by Tat-NR2B9c to the same extent in 
SNL and sham rats. These effects resemble those exerted by the 
NMDA  antagonist  MK-801  which  inhibits  postdischarge  and 
wind-up as well as mechanically and thermally evoked responses 
of WDR neurons equally in both SNL and sham rats.23 A more 
recent study showed that the specific NR2B antagonist, Ro-256981, 
reduced C-fiber-evoked neuronal responses and blocked spinal 
LTP identically in naive and SNL rats.12 Since the neuronal effects 
of Tat-NR2B9c do not differ following neuropathy, it may seem 
that coupling between NR2B subunits and PSD-95 is also not 
altered. However, major changes in connectivity between primary 
afferents and spinal neurons have occurred following neuropa-
thy. Two thirds of the input from the sciatic nerve has effectively 
been eliminated in the SNL model. Even within the L4 spinal seg-
ment, although afferent inputs are maintained, these are reduced 
because the ligated L5 and L6 spinal nerves cross-innervate this 
segment.24,25  Despite  this,  baseline  responses  of  WDR  neurons 
were similar in SNL and sham rats, suggesting that some compen-
sation in spinal excitability has occurred in neuropathic rats to 
counter the loss of peripheral input. Whether such compensation 
involves  altered  interactions  between  NR2B-subtype  receptors 
and PSD-95 remains to be elucidated.
Behavioral analyses confirmed that unilateral mechanical and 
cold hypersensitivity develops by day 2 following surgery in SNL 
rats and is maintained for the 2 weeks of testing. Spinal administra-
tion of Tat-NR2B9c, 2 weeks after surgery, via a single intrathecal 
injection, attenuated both mechanical and cold hypersensitivity of 
the injured paw, while the control peptide, Tat-NR2BAA, had no 
effect at all. PWTs were increased and responses to acetone were 
reduced toward baseline levels and those of the uninjured paw. 
These  effects  began  30  minutes  after  drug  administration,  con-
sistent with the onset of biochemical disruption between PSD-95 
and NR2B subunits, and lasted for the full 5-hour testing period. 
Reversal of nerve injury-induced mechanical and thermal hyper-
sensitivity by an NR2B-selective antagonist also begins ~30 minutes 
after administration.12,26 Together, these results confirm the key role 
of spinal NR2B-subtype receptors in chronic neuropathic pain.
The contribution of PSD-95-mediated protein interactions to 
inflammatory pain was indicated through the use of an alterna-
tive peptide, Tat-PSD-95 PDZ2, which mimics the second PDZ 
domain of PSD-95.27 However, the analgesic effect of this peptide 
may involve disruption of binding of PSD-95 to any number of sig-
naling proteins, including Shaker-type K+ channels28 and nNOS,29 
which interact with PSD-95 via its second PDZ domain. A cyclic 
peptide, CN2097, which blocks interactions at all PDZ domains 
of PSD-95, has been shown to reduce neuropathic pain, though 
again, the particular binding proteins involved in this inhibitory 
effect were not identified.18 We are confident that our results are 
due to a more specific disruption of NR2B and PSD-95 interac-
tions, since our Tat-NR2B9c peptide mimics the specific C-tail of 
NR2B subunits, so having no effect on the binding of PSD-95 to 
even NR2A subunits.30 We expect that other PSD-95 interactions 
would also remain intact.
The formalin model31 produces a biphasic response, electro-
physiologically in single neurons, as well as behaviorally in awake 
animals. Tat-NR2B9c selectively reduced the 2nd phase of the for-
malin response, thought to represent central sensitization,19,20 an 
effect which mimics that of NR2B-subtype receptor antagonism 
and genetic knockdown.26,32 Surprisingly, mutant mice expressing 
a PSD-95 protein truncated at the third PDZ domain were found 
to display normal behavioral responses to formalin.33 However, 
the  truncated  protein,  with  the  first  two  PDZ  domains  intact, 
may still be present at synapses since these first two domains of 
PSD-95 are required for synaptic targeting, while domain three is 
dispensable.34 In addition, the binding capacity at each individual 
PDZ domain independently contributes to synaptic clustering of 
the protein35 so that any loss of the third PDZ domain of PSD-95 
may not affect its binding to NMDA receptors. Alternatively, if a 
truncated PSD-95 protein can no longer bind NR2 subunits or be 
clustered in synaptic regions, other related proteins may compen-
sate for this loss. For example, PSD-93 is known to be important 
for inflammatory pain.36 Notably, Garry and colleagues33 measured 
only formalin-induced lifting and flinching behavior, a spinally 
mediated reflex response which we found to be infrequent and 
which was unaltered by Tat-NR2B9c. Licking and biting behavior, 
more of an active response requiring higher processing, predomi-
nated and this behavior exactly paralleled the neuronal firing and, 
significantly, was sensitive to inhibition by Tat-NR2B9c. Therefore, 
the seemingly conflicting results of these studies may simply reflect 
a difference in the behavioral end point measured. Interestingly, 
pain induced by intrathecal NMDA or nerve injury was reduced 
in these PSD-95 mutant mice,33 suggesting that individual PDZ 
domains of PSD-95 may contribute to different pain states.
Both the NR2B subunit and PSD-95 are distributed through-
out the gray matter of the dorsal horn but are most densely con-
centrated in superficial laminae,37,38 ideally positioned to receive 
inputs from terminating nociceptors. We confirmed coimmuno-
precipitation of PSD-95 and NR2B subunits in spinal neurons in 
accordance with previous work.39 The deep dorsal horn neurons 
we recorded most likely receive nociceptive inputs via interneu-
rons,40,41  whereas  a  relatively  smaller  number  may  synapse 
directly with terminating nociceptors via their dorsally extending 
dendrites.42
Our electrophysiological studies showed that 12.5 ng of Tat-
NR2B9c reduced wind-up by ~50% in all groups, suggesting that 
this dose was perhaps submaximal. Even at this dose, however, 
we saw some significant effects in the behavioral formalin test. 
Indeed a higher dose (125 ng) produced an even larger behavioral 
effect; therefore, we used this higher dose in the neuropathic pain 
behavi  oral study. Higher drug doses are often required in behav-
ioral studies compared to electrophysiological experiments, since 
in  behavioral  studies  smaller  injection  volumes,  lower  spatial 
access of the drug and movement of the animal limits the time 
for the drug to reach its target. In contrast, drug administration Molecular Therapy  vol. 19 no. 10 oct. 2011           1789
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during electrophysiology is into a static system, i.e., a laminectomy 
exposing the surface of the cord with the dura removed, where 
minimal movement of fluid occurs for the whole duration of the 
recording and thus less removal of drug. Even at the higher behav-
ioral dose, though, Tat-NR2B9c did not alter the performance of 
rats on the rotarod, indicating a lack of adverse locomotor effects 
which are commonly associated with conventional NMDA antag-
onists. Such drugs, for example MK-801 and ketamine, produce 
motor dysfunction at doses which are analgesic in the formalin 
test and neuropathic pain models.6,11
At  present,  the  precise  downstream  signaling  mechanisms 
by  which  coupling  between  NR2B-containing  NMDA  receptors 
and PSD-95 promotes nociceptive hypersensitivity are unknown. 
However,  previous  studies  employing  Tat-NR2B9c  may  suggest 
which  intracellular  molecules  and  pathways  are  involved.  Tat-
NR2B9c  is  neuroprotective  and  prevents  the  NMDA-dependent 
generation of nitric oxide in cortical cultures,30 while reducing gluta-
mate-induced phosphorylation of the extracellular signal-regulated 
kinase in striatal neurons.43 Additionally, PSD-95 mutant mice fail 
to exhibit increased Ca2+/calmodulin-dependent kinase II activity 
following nerve injury.33 Both extracellular signal-regulated kinase 
and Ca2+/calmodulin-dependent kinase II have key roles in central 
sensitization.44,45 Phosphatidylinositol 3-kinase, another mediator 
of central sensitization,46 has also been shown to bind to PSD-95 
in contributing to formalin-induced pain.47 Alternatively, binding 
of PSD-95 to NMDA subunits stabilizes the receptor in the cell 
membrane.48 Thus Tat-NR2B9c may decrease neuronal hyperexcit-
ability by interfering with membrane insertion of NMDA receptors. 
However, the fact that Tat-NR2B9c does not affect NMDA-mediated 
excitatory postsynaptic currents or Ca2+ influx in the hippocampus 
may suggest otherwise.30 Disruption of downstream intracellular 
signaling is the more likely mechanism of action.
Importantly,  we  have  demonstrated  that  NMDA  receptor-
dependent phenomena, such as wind-up and central sensitiza-
tion, can be prevented without receptor blockade, a likely cause of 
the neurological side effects associated with NMDA antagonists. 
Tat-NR2B9c, a mimetic peptide which disrupts binding specifi-
cally between NR2B-containing NMDA receptors and PSD-95, 
reversed nerve injury-induced neuropathic pain without adverse 
locomotor effects. Therefore, mimetic peptides, particularly those 
targeting interactions within the NMDA receptor complex, should 
be investigated further as novel analgesics for the clinical treat-
ment of chronic pain.
MAterIAls And Methods
Animals. Experiments were conducted in adult male Sprague–Dawley rats 
(Central Biological Services, University College London, or Harlan, UK), 
housed in standard laboratory conditions with free access to food and 
water. Experimental procedures were approved by the UK Home Office 
and followed guidelines under the International Association for the Study 
of Pain.49
Synthesis of Tat-NR2B9c and Tat-NR2BAA peptides. Tat-NR2B9c peptide 
comprises the final nine amino acids of the NR2B subunit cytoplasmic tail 
(KLSSIESDV), including the PSD-95 PDZ domain-binding motif (ESDV). 
This sequence is conjugated to a HIV-1 virus coat protein, Tat, transduc-
tion domain (YGRKKRRQRRR), for intracellular delivery.50 The full pep-
tide is 20 amino acids (YGRKKRRQRRRKLSSIESDV) in length. A control 
peptide, Tat-NR2BAA, was synthesized with a double substitution in the 
PDZ domain-binding motif (EADA), thereby rendering it unable to bind 
to its target and being inactive (YGRKKRRQRRRKLSSIEADA). Peptides 
were synthesized using an ACT 396 peptide synthesizer to >95% purity 
with  high-performance  liquid  chromatography  and  mass  spectrometry 
analysis (Wolfson Institute for Biomedical Research, University College 
London). Peptides were dissolved in phosphate-buffered saline.
In  vivo  electrophysiology—set-up.  Rats (220–250 g) were anesthetized 
using 4–5% isoflurane (66% N2O and 33% O2) and, once areflexic, a tra-
cheal cannula was inserted. Rats were placed in a stereotaxic frame and 
core body temperature was maintained at 37 °C using a feedback-heating 
blanket. Anesthesia was reduced to 2.5% isoflurane, and a laminectomy 
was performed at the L1–L3 vertebral level to expose the L4–L5 segments 
of the spinal cord. For the remainder of the experiment anesthesia was 
maintained at 1.5% isoflurane.
Extracellular  recordings  from  single  convergent  deep  dorsal  horn 
(>600 μm) WDR neurons, identified by tapping at the hindpaw receptive 
field, were made using parylene-coated tungsten electrodes (A-M Systems, 
Sequim, WA). WDR neurons respond to both innocuous and noxious 
stimulation in a graded manner, and can respond to various stimulus 
modalities  including  mechanical,  thermal,  electrical  and  chemical. 
Data were captured and analyzed by a CED 1401 interface coupled to a 
Pentium computer with Spike 2 software (Cambridge Electronic Design, 
Cambridge, UK; PSTH and rate functions). In all electrophysiological 
experiments, “n” refers to the total number of cells recorded.
Electrical stimulation of hindpaw to induce wind-up. A train of 16 trans-
cutaneous electrical stimuli (2 ms wide pulses, 0.5 Hz) was applied at three 
times the threshold current for C-fibers via two stimulating needles inserted 
under the skin of the hindpaw. A poststimulus histogram (Supplementary 
Figure  S2)  was  constructed  and  Aβ-  (0-20 ms),  Aδ-  (20–90 ms),  and 
C-fiber (90–300 ms) evoked responses were separated and quantified on 
a basis of latency. Responses occurring after the C-fiber latency band were 
taken to be the postdischarge of the cell (300–800 ms). Input (nonpotenti-
ated response) was quantified as the response after the first stimulus × 16. 
Wind-up was calculated as: (number of APs after 16 stimuli)—[number 
of AP after the first stimulus × 16 (i.e., input)]. Stable control responses 
to electrical stimuli were established at 10 minute intervals before drug 
administration. Following application of the drug, tests were continued at 
10 minute intervals for a further 2 hours.
In vivo electrophysiology—SNL model. Electrophysiological recordings 
of WDR neurons were conducted in the left side of the dorsal horn, ipsi-
lateral to the site of nerve injury, in both SNL and sham-operated animals 
on postoperative days 15–18. Rats weighed between 250 and 300 g at this 
point. Electrical and natural tests were conduced in separate animals to 
avoid overstimulation and sensitization of the sensory system. Only one 
cell was recorded per animal.
Transcutaneous electrical stimuli were applied as above. The latency 
band for C-fibers was increased to 90–350 ms to allow for the larger size 
of the animals. The latency for postdischarge was 350–800 ms. Input and 
wind-up were calculated as before. Drug was applied to the cord following 
the establishment of stable control responses and electrical tests were 
continued at 10 minute intervals for 1 hour.
In  a  separate  set  of  SNL-  and  sham-operated  animals,  neuronal 
responses  to  natural  stimuli  were  assessed.  The  hindpaw  peripheral 
receptive field was stimulated using natural stimuli, which extended from 
the non-noxious to noxious range. Brushing of the receptive field for 
10 seconds was used to produce a dynamic mechanical stimulus. Static 
mechanical stimulation was achieved by application of von Frey filaments 
1, 8, 15, and 26 g (9.8, 78.5, 147.1 and 255 mN, respectively; Touch-Test, 
North Coast Medical, San Jose, CA). Filaments 1 and 8 g are considered 
innocuous while filaments 15 and 26 g are noxious. Each filament was 1790  www.moleculartherapy.org  vol. 19 no. 10 oct. 2011                   
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applied in ascending order for 10 seconds. Next, the receptive field was 
stimulated  thermally  with  the  following  temperatures:  35,  40,  45  and 
48 °C. Temperatures including 45 °C and above are considered noxious. 
Heat was applied with a constant water jet onto the centre of the receptive 
field, again in ascending order for a period of 10 seconds/stimulus. Drug 
administration  occurred  following  the  establishment  of  stable  control 
responses and natural tests (brush, von Frey filaments and heat) were 
continued at 20 minute intervals for 1 hour.
Neuronal formalin test. WDR neurons from adult rats (220–250 g) were 
characterized before formalin administration. Transcutaneous stimulating 
needles were used to electrically stimulate the receptive field (as above) 
and responses were monitored to thermal stimulation using a constant jet 
of water onto the centre of the receptive field to indicate a strong C-fiber 
innervation of the WDR neuron, which is required for the response to sub-
cutaneous formalin.19
Following  cell  characterization,  rats  were  pretreated  with  Tat-
NR2B9c or Tat-NR2BAA, 20 minutes before the injection of formalin. 
A separate group of control animals received no drug. Formalin (5%, 
50 μl) was prepared from a 37% formaldehyde solution and then injected 
subcutaneously into the hindpaw receptive field. The firing response of the 
WDR neuron was recorded for the subsequent 70 minutes after formalin 
injection. Activity was displayed as a rate recording and quantified in 10 
minute time bins.
Behavioral formalin test. Rats (220–250 g) were placed in a Plexiglas box 
and were allowed to acclimatize for 30 minutes. Rats were then lightly 
anesthetized with isoflurane and injected intrathecally (lumbar puncture 
method) with either 10 μl of Tat-NR2B9c (12.5 ng, n = 10 or 125 ng, n = 6) 
or 10 μl of Tat-NR2BAA (1.25 μg, n = 11). Experimenters were blind to 
treatment for the whole testing period. Twenty minutes later, rats received 
a subcutaneous injection of 50 μl of formalin (5%) into the plantar surface 
of the right hindpaw. Lifting, flinching, licking, and biting of the injected 
paw were monitored by measuring the total duration of the response in 
seconds during the 60 minute period following formalin administration. 
Data was captured in 5 minute time bins.
SNL model of neuropathic pain. Male Sprague–Dawley rats (130–150 g; 
Central Biological Services, University College London, UK) underwent 
surgery for ligation of L5 and L6 spinal nerves, or sham operation21. Under 
isoflurane anesthesia (1:1 O2:N2O, 5% isoflurane for induction, 2% for 
maintenance), rats were placed in a prone position and the left paraspinal 
muscles were separated from the spinal processes at the L4–S2 vertebral 
level. Part of the L6 transverse process was carefully removed and the left 
L4–L6 spinal nerves were identified. The L5 and L6 spinal nerves were 
isolated and tightly ligated with 6–0 silk thread, distal to the dorsal root 
ganglion and proximal to the formation of the sciatic nerve. The procedure 
for sham operation was identical, except for the ligation of spinal nerves, 
which was omitted. Animals were allowed to recover in a warm chamber 
and were checked for signs of motor impairment, such as dragging or non-
weight bearing of the affected hindpaw.
Behavioral assessment of mechanical and cold hypersensitivity. Four 
days before SNL surgery, PWTs and cold sensitivity were assessed for both 
hindpaws of rats. Following SNL surgery, testing was repeated in the post-
operative period on days 2, 7, 10, and 14/16 to observe the development of 
mechanical and cold hypersensitivity in the ipsilateral injured paw versus 
the contralateral paw. Drug effects were assessed on days 14/16.
PWT. Mechanical hypersensitivity of SNL rats was detected by measuring 
PWTs. von Frey filaments were applied 10 times to the plantar surface of 
each hindpaw from below, in ascending order. The PWT was determined 
by recording the first von Frey filament to produce 5 positive responses out 
of 10. A positive response was withdrawal as well as licking and/or biting 
of the stimulated hindpaw, indicative of nocifensive behavior. A cutoff was 
set at 15 g (147.1 mN) to avoid tissue damage.
Acetone drop test. Cold hypersensitivity of SNL rats was assessed by the 
application of a single drop of acetone, five times, to the plantar surface 
of the ipsilateral and contralateral hindpaws. Acetone was delivered from 
below through a 10 cm piece of tubing connected to a 0.5 ml syringe. Each 
rat was given a score out of 5 for the number of positive responses for each 
hindpaw. A positive response was the same as with the application of von 
Frey filaments except that a short delay would often be noted between 
application of the acetone drop and foot withdrawal. This is due to the fact 
that the cooling stimulus is brought about by evaporation of the acetone 
drop.
On day 14/16, following initial sensory testing, animals were treated 
with either Tat-NR2B9c or Tat-NR2BAA (both 125 ng in a volume of 10 μl, 
n = 8 in each group) via intrathecal lumbar puncture. Sensory testing 
then continued and PWTs and responses to acetone were assessed at 30 
minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours and 5 hours 
after intrathecal injection. Experimenters were blind to treatment for the 
full duration of the experiment.
Assessment  of  locomotor  function—rotarod.  Locomotor function and 
motor effects of drugs were assessed using an accelerating rotarod device 
(Rotarod 7750; Ugo Basile, Comerio, Italy). The apparatus was set to accel-
erate from 0 to 20 rpm over 60 seconds and the latency to fall was moni-
tored with a maximum cutoff of 90 seconds. Rats (200–220 g) underwent 
a training period on days −3 and −1 before testing of drug effects in order 
to ensure that they could remain on the rotarod for a minimum of 60 sec-
onds. Locomotor function was assessed following intrathecal administra-
tion of Tat-NR2B9c (125 ng, 10 μl, n = 4) via lumbar puncture. Tests were 
carried out before injection (baseline) and at 20, 40, 60 and 120 minutes 
postinjection.
Drug administration—in vivo electrophysiology. In all electrophysiologi-
cal experiments, drugs were applied directly to the surface of the spinal cord 
of rats, after removal of any residual cerebrospinal fluid, in a volume of 50 μl, 
using a Hamilton syringe. Before drug administration, control values were 
obtained by averaging the responses from the last three neuronal tests.
Intrathecal drug administration for behavioral studies—lumbar punc-
ture method. In all behavioral pharmacological studies, drugs were deliv-
ered via intrathecal injections performed by direct lumbar puncture. Briefly, 
rats were lightly anesthetized with isoflurane. Their backs were shaved and 
the skin was cleansed with gauze soaked in an antimicrobial solution. A 
25-gauge needle connected to a syringe was then inserted into the suba-
rachnoidal space between the spinal processes of the L5 and L6 lumbar 
vertebrae. Drug was injected in a volume of 10-μl, eliciting a tail-flick. The 
syringe was held in position for a few seconds after the injection.
Western immunoblotting and immunoprecipitation. Rats anesthetized 
with urethane were sacrificed by decapitation and fresh tissues (spinal dor-
sal horn, dorsal root ganglion, or hippocampus) were dissected out and 
snap frozen. Two additional groups of rats received Tat-NR2BAA (125 ng) 
or  Tat-NR2B9c  (125 ng)  via  intrathecal  lumbar  puncture,  20  minutes 
before being sacrificed and dissection of tissue, under urethane anesthesia. 
Tissue was subsequently homogenized in RIPA (radioimmunoprecipita-
tion assay) buffer (50 mmol/l Tris–HCl pH 7.5, 150 mmol/l NaCl, 1 mmol/l 
EDTA, 1% NP-40, 0.1% SDS + 0.5% deoxycholic acid + complete protease 
inhibitor cocktail) using a glass homogenizer. Homogenates were then cen-
trifuged at 14,000 rpm for 10 minutes at 4 °C and supernatants containing 
tissue lysates were collected. Spinal whole cell lysates were next titrated to 
determine their protein concentrations using a bicinchoninic acid protein 
assay kit (Thermo Fisher Scientific, Cramlington, UK).
For  western  immunoblotting,  laemmli  loading  buffer  was  added 
to dorsal horn, dorsal root ganglion and hippocampus protein lysates 
(40 μg) and samples were incubated at 70 °C for 30 minutes. Samples were 
then loaded onto 8% gels and separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis.Molecular Therapy  vol. 19 no. 10 oct. 2011           1791
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For immunoprecipitation, magnetic Dynabeads Protein G (Invitrogen, 
Paisely,  UK)  were  washed  and  coupled  with  5 μg  of  rabbit  anti-NR2B 
antibody  (06-600;  Upstate,  Lake  Placid,  NY)  by  incubation  at  room 
temperature for 40 minutes. Next 500 μg of spinal cord dorsal horn lysate 
was added to the antibody–dynabeads complex and allowed to incubate 
overnight for capture of target antigen. Captured protein was eluted from the 
dynabeads by resuspension in 40 μl of laemmli loading buffer and heating 
at 70 °C for 30 minutes. Samples were then separated on 8% gels by sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis. Normal spinal lysate 
samples (40 μg) were run alongside immunoprecipitated samples to act as 
positive controls.
Following electrophoresis, proteins were transferred to nitrocellulose 
membranes, which were then incubated with primary antibody overnight 
at 4 °C. Antibodies used were mouse anti-NR2B (1:500, 75–101; Neuromab, 
Davis, CA), rabbit anti-PSD-95 (1:1,000, ab18258; Abcam, Cambridge, 
UK), rabbit anti-nNOS (1:3,000, 07-571; Millipore, Billerica, MA), rabbit 
anti-CREB  (1:500,  ab5803;  Abcam),  rabbit  anti-P2X3  (1:500,  ab10269; 
Abcam) and rabbit anti-neuronal βIII-tubulin (1:3,000, ab18207; Abcam), 
which served as a loading control. Following incubation with dye-linked 
donkey anti-rabbit IR800 or goat anti-mouse IR600 secondary antibody, 
proteins were revealed using the Odyssey fluorescence detection system 
(Licor, Cambridge, UK).
Statistical analysis. Data are presented as mean ± SEM. Effects of Tat-
NR2B9c and Tat-NR2BAA following electrical stimulation of the hindpaw 
were assessed by one-way repeated measures analysis of variance (one-way 
RM ANOVA) followed by Bonferroni’s multiple comparison post-tests. 
Cell characteristics were compared by Student’s unpaired t-tests (wind-
up studies and brush-evoked responses), one-way ANOVA followed by 
Bonferroni’s post-test (neuronal formalin test) or two-way RM ANOVA 
(evoked  responses  to  graded  mechanical  and  thermal  stimulation). 
Formalin neuronal and behavioral response time course data was com-
pared between treatment groups and analyzed by two-way RM ANOVA 
followed by Bonferroni’s post-test. Total activity in the 1st and 2nd phases 
was compared between treatment groups by quantifying the area under 
each curve and analyzed by one-way ANOVA followed by Bonferroni’s 
post-test. Effects of Tat-NR2B9c following natural stimulation (von Frey 
and heat) of the hindpaw were assessed by two-way RM ANOVA followed 
by Bonferroni post-tests. Effects on brush-evoked responses were assessed 
using one-way RM ANOVA followed by Bonferroni post-tests. Two-way 
RM  ANOVA  followed  by  Bonferroni  post-tests  was  used  to  compare 
PWTs and responses to acetone between ipsilateral and contralateral paws 
in SNL rats as well as effects of Tat-NR2B9c and Tat-NR2BAA. One-way 
RM ANOVA followed by Dunnett’s post-test was used to assess effects of 
Tat-NR2B9c in the rotarod locomotor function test. Statistical analyses 
were carried out using GraphPad Prism v.4 software (GraphPad Software, 
La Jolla, CA).
suPPleMentArY MAterIAl
Figure S1.  Intrathecal  Tat-NR2B9c  selectively  reduces  active  pain-
related licking and biting behaviors following intraplantar formalin.
Figure S2.  Representative poststimulus histogram (PSTH) of electri-
cally evoked responses of a WDR neuron to electrical stimulation of 
the hindpaw.
Table S1.  Predrug control responses induced by transcutaneous elec-
trical stimulation of the hindpaw receptive field of WDR neurons in 
naive rats.
Table S2.  Formalin  electrophysiology  experiment  WDR  cell 
characteristics.
Table S3.  Predrug control responses induced by transcutaneous elec-
trical stimulation of the hindpaw receptive field of WDR neurons in 
sham and SNL rats.
Table S4.  Predrug control responses induced by natural stimulation 
of the hindpaw receptive field of WDR neurons in sham and SNL rats.
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